Jefferies Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $105

Benzinga Newsdesk www.benzinga.com Positive 84.1%

Neg 0% Neu 0% Pos 84.1%

Jefferies analyst Akash Tewari maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $104 to $105.